SavedAdd your journal

Journals / Türk Oftalmoloji Dergisi / 2012 / Cilt: 42 - Sayı: 3

Comparison of ranibizumab and pegabtanib sodium monotherapies in terms of rates of stabilization after the first three doses

İlk üç doz sonrası stabilizasyon oranları açısındanranibizumab ve pegaptanib sodyum monoterapilerinin karşılaştırılması

Hüseyin ASLANKARA
Durgül TÜRÜTHAN
Süleyman KAYNAK
Nilüfer KOÇAK
Pages
211–215
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

There were statistically significant changes in VA and CMT after ranibizumab treatment (p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Purpose: To evaluate the short-term efficacy of intravitreal ranibizumab and pegaptanib Na injection in the treatment of wet type of age- related macular degeneration (AMD).
📊
Key Findings & Data:Material and Method: We retrospectively reviewed the records of 30 patients (30 eyes) who were treated with monthly injections of intravitreal ranibizumab for three months and 30 patients (30 eyes) who were treated with intravitreal pegaptanib Na at 6-week intervals for a period of 18 weeks for wet-type AMD.
💡
Conclusion & Impact:There were statistically significant changes in VA and CMT after ranibizumab treatment (p
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Purpose: To evaluate the short-term efficacy of intravitreal ranibizumab and pegaptanib Na injection in the treatment of wet type of age- related macular degeneration (AMD). Material and Method: We retrospectively reviewed the records of 30 patients (30 eyes) who were treated with monthly injections of intravitreal ranibizumab for three months and 30 patients (30 eyes) who were treated with intravitreal pegaptanib Na at 6-week intervals for a period of 18 weeks for wet-type AMD. Baseline clinical findings and demographic data, visual acuity (VA) and central macular thickness (CMT) before and after treatment, and stabilization of VA rate after treatment were evaluated.Results: There were no statistically significant differences in age, sex and in terms of baseline types of angiographic lesions between the groups. Following ranibizumab treatment, VA with logMAR changed from 0.83±0.60 to 0.58±0.48. Stabilization of VA was achieved in 96.7% of patients (fewer than 15 letters lost). Mean CMT decreased from 487.23±72.03 μm to 338.70±91.56 μm. There were statistically significant changes in VA and CMT after ranibizumab treatment (p

Özet

Amaç: Yaş tip yaşa bağlı maküla dejenerasyonu (YBMD) olan hastaların tedavisinde intravitreal pegaptanib Na ve intravitreal ranibizumab tedavilerinin kısa dönem etkinliklerini değerlendirmek. Gereç ve Yöntem: Yaş tip YBMD nedeniyle aylık intravitreal ranibizumab injeksiyonu ile 3 ay boyunca tedavi edilen 30 hastanın 30 gözü ve 6 hafta arayla intravitreal pegaptanib Na ile 18 hafta boyunca tedavi edilen 30 hastanın 30 gözünün kayıtları retrospektif olarak incelendi. Hastaların tedavi öncesi klinik muayene ve demografik özellikleri, tedavi öncesi ve son kontroldeki görme keskinliği (GK) ve santral maküla kalınlığındaki değişim (SMK) ve tedavi sonrasında GK stabilizasyon oranları değerlendirildi.Sonuçlar: Gruplar arasında yaş, cinsiyet ve tedavi öncesinde anjiyografik lezyon tipleri açısından istatistiksel anlamlı fark yoktu. Ranibizumab tedavisi sonrası GK logMAR ile 0,83±0,60’dan 0,58±0,48’e değişti. Hastaların %96,7’sinde GK stabilizasyon sağlandı (15 harften az kayıp). Ortalama SMK 487,23±72,03 μm’dan 338,70±91,56 μm’a geriledi. Ranibizumab tedavisiyle GK ve SMK’de istatistiksel anlamlı değişiklik görüldü (p

🔖

Cite This Article

ASLANKARA, H., TÜRÜTHAN, D., KAYNAK, S., KOÇAK, N. (2022). Comparison of ranibizumab and pegabtanib sodium monotherapies in terms of rates of stabilization after the first three doses. Türk Oftalmoloji Dergisi, Cilt: 42 - Sayı: 3, 211–215. https://ajindex.com/articles/638263

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Ambati J, Ambati BK, Yoo SH, Ianchulev S, Adamis AP. Age-related macular degeneration: etiology, pathogenesis, and therapeutic strategies. Surv Ophthalmol. 2003;48:257-93
  2. Resnikoff S, Pascolini D, Etya’ale D, et al. Global data on visual impairment in the year 2002. Bull World Health Organ. 2004;82:844-51
  3. Ferris FL, Fine SL, Hyman L. Age-related macular degeneration and blindness due to neovascular maculopathy. Arch Ophthalmol. 1984;102:1640-2
  4. Adamis AP, Shima TS. The role of vascular endothelial growth factor in ocular disease. Retina. 2005;25:111–8
  5. Aiello LP, Northrup JM, Keyt BA, et al. Hypoxic regulation of vascular endothelial growth factor in retinal cells. Arch Ophthalmol. 1995;113:1538-44
  6. Otani A, Takagi H, Oh H, et al. Vascular endothelial growth factor family and receptor expression in human choroidal neovascular membranes. Microvasc Res. 2002;64:162-9
  7. Preclinical and phase IA clinical evaluation of an anti-VEGF aptamer (EYE001) for the treatment of exudative age-related macular degeneration. Eyetech study group. Retina. 2002;22:143-52
  8. Gaudreault J, Fei D, Rusit J, Suboc P, Shiu V. Preclinical pharmacokinetics of Ranibizumab (rhuFabV2) after a single intravitreal administration. Invest Ophthalmol Vis Sci. 2005;46:726-33. 9. van Wijngaarden P, Coster DJ, Williams KA. Inhibitors of ocular neovascularization: Promises and potential problems. JAMA. 2005;293:1509-13
  9. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Eng J Med. 2006;355:1419-31
  10. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1432-44
  11. Fung AE, Lalwani GA, Rosenfeld PJ, et al. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol. 2007;143:566-83
  12. Heier JS, Antoszyk AN, Pavan PR, et al. Ranibizumab for Treatment of Neovascular Age-Related Macular Degeneration. A Phase I/II Multicenter, Controlled, Multidose Study. Ophthalmology. 2006;113:633-42
  13. Bhatnagar P, Spaide R, Takahashi BS, et al. Ranibizumabfor treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina. 2007;27:846-50
  14. Koçak N, Kaya M, Selver ÖB, ve ark. Koroid neovaskülarizasyonunda ranibizumab monoterapisinin erken dönem sonuçları. Turk J Ophthalmol. 2011;41:10-5
  15. Grago